Conference/Scientific publicationPentixapharm to Present First-in-Class Glycan-Dependent CD24 Antibody GT-008 for Solid Tumors at AACR 2025 25.04.2025 / 15:39 CET/CESTThe issuer is solely responsible ...

The Institute of Biotechnology and Genetic Engineering (IBGE) at Gazipur Agricultural University (GAU) celebrated World DNA ...

What if business leaders approached strategy the way scientists design gene delivery vectors? In biotechnology, precision, ...

All posters will be available on the ‘Posters and Publications’ page of Cogent’s website. New Leadership Appointments Cogent also announced today that Ray Frost has joined Cogent as Senior Vice ...

African bishops’ conferences, largely among the church’s most conservative, pushed back against Francis' positions. After he ...

The US Food and Drug Administration on Wednesday approved a cancer drug developed by China-based Akeso Inc, marking a ...

Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") , a clinical-stage biotechnology company leveraging its proprietary DiffuSpheretm technology designed to optimize drug delivery for ...

Pittsburgh biotech firms see potential benefits from upcoming tariffs and reshoring efforts, despite uncertainties in NIH ...

BioAtla (BCAB) announced preclinical poster presentations at the upcoming 2025 American Association for Cancer Research to be held at the ...

BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, ...

As of today, Kelun-Biotech has initiated 8 registrational clinical studies in China. MSD has initiated 12 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab or ...

Adcentrx Therapeutics ("Adcentrx"), a clinical-stage biotechnology company redefining Antibody-Drug Conjugate (ADC) therapies for cancer treatment and other life-threatening diseases, will present the ...